10x Genomics and CareDx have entered into a partnership to develop and commercialize the ImmuneScape™ program, a multi‑omics platform that combines 10x Genomics’ Xenium spatial and Chromium Flex single‑cell technologies with CareDx’s precision‑medicine expertise. The platform is designed to profile immune responses in transplant rejection, focusing on antibody‑mediated rejection and microvascular inflammation, and to assess drug response at unprecedented resolution.
The collaboration aligns with both companies’ strategic priorities. CareDx, a leader in transplant diagnostics, seeks to deepen its understanding of rejection biology and accelerate the development of new diagnostic tools. 10x Genomics, which has traditionally served academic and research customers, gains a foothold in the clinical and biopharma sectors, potentially opening new revenue streams beyond its core research market. The partnership taps into a sizable opportunity: the global transplant diagnostics market is projected to reach $3.92 billion by 2032, while the single‑cell multi‑omics market is expected to grow to $20.98 billion by 2031.
Financially, 10x Genomics reported Q3 2025 revenue of $149.0 million, up from $142.5 million in the prior quarter, and an EPS of –$0.22 versus a consensus of –$0.15. CareDx posted Q3 2025 revenue of $100.1 million, beating expectations, and an EPS of $0.28 against a forecast of $0.13. The partnership is expected to generate incremental revenue for both firms, with 10x Genomics potentially monetizing its platform in a new customer base and CareDx leveraging ImmuneScape insights to expand its diagnostic portfolio.
John Hanna, President and CEO of CareDx, said the collaboration “marks a meaningful step in advancing precision transplant care. By uniting CareDx’s clinical and diagnostic expertise with 10x Genomics’ transcriptomics technologies, we are building on a robust scientific foundation to drive future organ‑health innovation across our diagnostic pipeline.” Serge Saxonov, Co‑founder and CEO of 10x Genomics, added that the partnership “opens a new window into the cellular and molecular signatures of rejection that have historically been impossible to measure, offering profound scientific impact and the potential to improve outcomes for transplant patients.”
Investors responded with mixed sentiment. While the partnership generated enthusiasm for its potential to unlock new diagnostic capabilities, concerns about CareDx’s forward‑looking profitability and the need for continued investment in research and development tempered enthusiasm. The market’s reaction reflected a balance between excitement over the strategic fit and caution regarding the companies’ near‑term financial outlook.
The ImmuneScape initiative positions both firms to influence the evolving landscape of transplant diagnostics. By integrating high‑resolution spatial and single‑cell data, the platform could accelerate the development of next‑generation tests that refine rejection subtyping and guide therapeutic decisions, potentially reshaping clinical practice and creating new revenue opportunities for both 10x Genomics and CareDx.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.